Market Challenges And Opportunities

Increasing investment and funding related to sterility testing is also expected to propel the market growth. For instance, in May 2019, Thermo Fisher Scientific Inc. announced to invest over US$ 50 million in its global bioproduction capabilities to offer additional capacity for manufacturing single-use bioprocess container (BPC) systems that are used for critical, sterile liquid-handling applications in the biopharmaceutical industry.

Moreover, in March 2019, Thermo Fisher Scientific Inc. announced to invest US$ 150 million in its Pharma Services business to offer additional capacity for sterile liquid and lyophilized product development and commercial manufacturing.